2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasms
10
Leukemia, Myeloid, Acute
6
Myelodysplastic Syndromes
2
Leukemia, Myelomonocytic, Chronic
2
Leukemia
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Lymphoma, T-Cell
1
Lymphoma
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Monocytic, Acute
1
Leukemia, Megakaryoblastic, Acute
1
Leukemia, Erythroblastic, Acute
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cytarabine
82
Etoposide
32
Daunorubicin
31
Idarubicin
26
Filgrastim
26
Mitoxantrone
22
Busulfan
18
Peripheral Blood Stem Cell Transplantation
17
fludarabine phosphate
14
Gemtuzumab
14
Cyclophosphamide
14
tipifarnib
11
Clofarabine
10
Azacitidine
10
Radiotherapy
9
Methotrexate
9
Gene Expression Profiling
9
sargramostim
8
Flow Cytometry
8
Granulocyte Colony-Stimulating Factor
7
Decitabine
7
Cyclosporine
7
alvocidib
6
Topotecan
6
Tacrolimus
6
Bortezomib
6
Antilymphocyte Serum
6
valspodar
5
aldesleukin
5
Vorinostat
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Myelomonocytic, Acute
×
BI 6727
×
Clear all
NCT02527174
2017-04-05
VIAC
University of Alberta
Phase 1
Withdrawn